How PD-L1 Biomarker Test Results Impact Clinical Management of Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
Linda Bosserman discusses the issues regarding the value of personalized care
Listen as Dr. Michaelis discusses the unique aspects of the system burdens of polycythemia vera, the difficult approach to treat and the options to treat.Supported through funding from Incyte